Drug Update Quizz 10Created on October 09, 2022BTK inhibitorIbrutinib - an oral Bruton's tyrosine kinase (BTK) inhibitor is currently (oct 2022) not approved for treatment of :- Mantle Cell Lymphoma with at least one prior therapy. Waldenström’s Macroglobulinemia Marginal Zone Lymphoma with at least one prior anti-CD20-based therapy. Chronic Graft Versus Host Disease in adult and pediatric patients age 1 year and older DLBCL patients with at least one prior anti-CD20-based therapy. Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD). It is not approved for DLBCL. Change/Click on page numbers below for next Question Pages: 1 2 3 4 5 6 7
